X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4889) 4889
Newsletter (1572) 1572
Publication (573) 573
Newspaper Article (137) 137
Book Review (109) 109
Book Chapter (53) 53
Magazine Article (22) 22
Trade Publication Article (12) 12
Conference Proceeding (11) 11
Reference (6) 6
Transcript (6) 6
Dissertation (4) 4
Book / eBook (3) 3
Report (2) 2
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
monoclonal antibodies (4129) 4129
humans (3317) 3317
index medicus (2875) 2875
cancer (2687) 2687
oncology (2053) 2053
research (1600) 1600
care and treatment (1554) 1554
cetuximab (1455) 1455
monoclonal-antibody (1356) 1356
animals (1322) 1322
colorectal cancer (1096) 1096
antibodies, monoclonal - therapeutic use (1056) 1056
chemotherapy (1027) 1027
epidermal growth factor (1011) 1011
growth-factor receptor (972) 972
female (912) 912
metastasis (841) 841
antineoplastic agents (839) 839
antineoplastic agents - therapeutic use (810) 810
antimitotic agents (808) 808
tumors (762) 762
health aspects (728) 728
pharmacology & pharmacy (711) 711
antibodies, monoclonal, humanized (710) 710
immunotherapy (677) 677
reports (646) 646
analysis (645) 645
oncology, experimental (627) 627
egfr (612) 612
receptor, epidermal growth factor - antagonists & inhibitors (612) 612
male (610) 610
cell line, tumor (601) 601
mice (588) 588
biological products (584) 584
monoclonal-antibodies (580) 580
drug therapy (577) 577
neoplasms - drug therapy (508) 508
monoclonal antibody (501) 501
colorectal neoplasms - drug therapy (497) 497
middle aged (495) 495
therapy (479) 479
antineoplastic agents - pharmacology (461) 461
proteins (446) 446
mutation (445) 445
antibodies, monoclonal - pharmacology (441) 441
genetic aspects (437) 437
aged (432) 432
clinical trials (432) 432
receptor, epidermal growth factor - metabolism (429) 429
drugs (428) 428
squamous cell carcinoma (420) 420
immunology (409) 409
medicine & public health (406) 406
expression (397) 397
cancer therapies (388) 388
antibodies (386) 386
bevacizumab (378) 378
antineoplastic combined chemotherapy protocols - therapeutic use (377) 377
cell lung-cancer (376) 376
immunoglobulins (372) 372
phase-ii trial (371) 371
antibodies, monoclonal - administration & dosage (363) 363
metastatic colorectal-cancer (356) 356
tyrosine kinase inhibitor (356) 356
medical research (347) 347
adult (344) 344
breast-cancer (343) 343
universities and colleges (343) 343
treatment outcome (339) 339
medicine, research & experimental (332) 332
article (325) 325
1st-line treatment (324) 324
trastuzumab (314) 314
panitumumab (313) 313
review (311) 311
antibodies, monoclonal - immunology (308) 308
clinical trials as topic (308) 308
antibodies, monoclonal - adverse effects (306) 306
colon cancer (304) 304
epidermal growth factor receptor (303) 303
colorectal-cancer (297) 297
apoptosis (296) 296
colorectal neoplasms - pathology (290) 290
biochemistry & molecular biology (288) 288
signal transduction (286) 286
breast cancer (285) 285
targeted therapy (281) 281
development and progression (275) 275
hematology, oncology and palliative medicine (275) 275
cell biology (263) 263
in-vivo (261) 261
biotechnology & applied microbiology (259) 259
neoplasms - immunology (257) 257
cancer research (256) 256
patients (256) 256
antitumor-activity (255) 255
radiotherapy (253) 253
lung cancer, non-small cell (252) 252
squamous-cell carcinoma (252) 252
receptor, epidermal growth factor - immunology (249) 249
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6496) 6496
Japanese (108) 108
Chinese (39) 39
French (30) 30
German (19) 19
Russian (4) 4
Spanish (4) 4
Polish (3) 3
Arabic (1) 1
Korean (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2004, Volume 351, Issue 4, pp. 337 - 345
In this randomized trial, cetuximab, a monoclonal antibody against the epidermal growth factor receptor, was given alone or in combination with irinotecan to... 
CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | MULTICENTER RANDOMIZED-TRIAL | PHASE-II TRIAL | TYROSINE KINASE | MONOCLONAL-ANTIBODY | ANTITUMOR-ACTIVITY | FLUOROURACIL-LEUCOVORIN | RESISTANT CHINESE-HAMSTER | Single-Blind Method | Adenocarcinoma - pathology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Topoisomerase I Inhibitors | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Neoplasm Metastasis | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - adverse effects | Exanthema - chemically induced | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Cetuximab | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Colorectal Neoplasms - pathology | Adenocarcinoma - mortality | Dosage and administration | Drug therapy, Combination | Research | Drug therapy | Colorectal cancer | Nuclear magnetic resonance--NMR | Epidermal growth factor
Journal Article
THERAPEUTIC DRUG MONITORING, ISSN 0163-4356, 08/2019, Volume 41, Issue 4, pp. 467 - 475
Background: Cetuximab (CTX) is a chimeric IgG1 Kappa monoclonal antibody used to treat head and neck cancer and colorectal cancer. Previous clinical studies... 
ASSAY | RATIONALE | PROGRESSION-FREE SURVIVAL | QUANTIFICATION | QUANTITATION | cetuximab | PHARMACOKINETICS INFLUENCES | MONOCLONAL-ANTIBODY | SERUM | SIL-CTX | Orbitrap | HRMS | LC-MS/MS METHOD | PHARMACOLOGY & PHARMACY | TOXICOLOGY | MEDICAL LABORATORY TECHNOLOGY | monoclonal antibody | BIOANALYSIS | Mass spectrometry | Usage | Liquid chromatography | Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2008, Volume 358, Issue 11, pp. 1109 - 1117
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 06/2014, Volume 124, Issue 6, pp. 2668 - 2682
Journal Article
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 10/2013, Volume 12, Issue 10, pp. 2187 - 2199
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2009, Volume 360, Issue 14, pp. 1408 - 1417
Journal Article
Journal Article